鐢㈠搧鍚嶇ū | BCL2鍒嗗瓙浼翠径瑾跨瘈铔嬬櫧5鎶楅珨 |
鑻辨枃鍚嶇ū | Anti-BAG5 |
瑕忔牸 | 0.2ml/200渭g |
婵冨害 | 1mg/1ml |
鍍规牸 | 渚嗛浕鍙韩鍙楀劒鎯� |
鑻辨枃鍚嶇ū Anti-BAG5
涓枃鍚嶇ū BCL2鍒嗗瓙浼翠径瑾跨瘈铔嬬櫧5鎶楅珨
婵� 搴� 1mg/1ml
瑕� 鏍� 0.2ml/200渭g
鎶楅珨渚嗘簮 Rabbit
鍏嬮殕椤炲瀷 polyclonal
浜ゅ弶鍙嶆噳 Human, Mouse, Rat, Chicken, Dog
鐢㈠搧椤炲瀷 涓€鎶�
鐮旂┒闋樺煙 鑵槫 绱拌優鐢熺墿 鍏嶇柅瀛� 绱拌優鍑嬩骸
铔嬬櫧鍒嗗瓙閲� predicted molecular weight: 51kDa
鎬� 鐙€ Lyophilized or Liquid
鍏� 鐤� 鍘� KLH conjugated synthetic peptide derived from humanBAG5
浜� 鍨� IgG
绱斿寲鏂规硶 affinity purified by Protein A
鍎� 瀛� 娑� 0.01M PBS, pH 7.4 with 10 mg/ml BSA and 0.1% Sodiumazide
鐢㈠搧鎳夌敤 WB=1:100-500 ELISA=1:500-1000 IP=1:20-100IHC-P=1:100-500 IHC-F=1:100-500 IF=1:100-500
锛堢煶锠熷垏鐗囬渶鍋氭姉鍘熶慨寰╋級
not yet tested in other applications.
optimal dilutions/concentrations should be determined by theend user.
淇濆瓨姊濅欢 Store at -46 掳C for oneyear.
鍒� 鍚� BAG family molecular chaperone regulator 5; BAG 5;BAG-5; BCL2 associated athanogene 5; KIAA0873; BAG5_HUMAN.
